Key takeaways New GLP-1 drugs are coming onto the market in 2026 and beyond These new products could widen up GLP-1 drugs to a much larger and different audience: creating an even bigger impact on F&B than seen to date and shifting who core users are New drugs could also have different impacts on how people react to food and drink: and therefore what they want and need from products
This cGMP-mediated increase in cellular antioxidant enzymes warrants further investigation to determine whether it plays a beneficial role in vivo , and whether it is relevant to the actions of receptor-mediated (particulate) guanylyl cyclase-activation pathways ( e.g ., through atrial natriuretic peptide) or soluble guanylyl cyclase (sGC) pathways ( e.g ., stimulated by NO ) that activate protein kinase G
avoid freezing, since freezethaw cycles degrade NAD+ in solution
Additionally, lipids play a crucial role in influencing the sensory characteristics of food products
33 , 38 , 39 , 40 , 41 , 42 , 43 , 44 GIP also enhances glucosestimulated insulin secretion in people without type 2 diabetes whereas this effect is diminished in people with type 2 diabetes, but unlike GLP1, it stimulates glucagon secretion in hypoglycaemic states
